Study reveals English proficiency, income, and area-level unemployment are among the influential factors and highlights need for tailored interventions to increase screening rates.
Duchenne muscular dystrophy drug from Nippon Shinyaku fails in rare confirmatory trial
Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease,
May 27, 2024